Neuberger Berman Group
MXCT icon

Neuberger Berman Group’s MaxCyte MXCT Stock Holding History

Neuberger Berman Group’s Portfolio MXCT Stock Details MXCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-151,706
Closed -$1.06M – 1905
2022
Q1 		$1.06M Buy
151,706
+3,459
+2% +$23.6K ﹤0.01% 1335
2021
Q4 		$1.51M Sell
148,247
-1,640
-1% -$17.6K ﹤0.01% 1253
2021
Q3 		$1.81M Buy
+149,887
New +$2.26M ﹤0.01% 1190

Other funds holding MXCT

CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VP
Vitruvian Partners London, United Kingdom $112M AUM 2.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RGI
River Global Investors London, United Kingdom $515M AUM 24.86% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Neuberger Berman Group's MXCT Position: Q2 2022 in Review

Neuberger Berman Group sold out of MaxCyte (MXCT) in Q2 2022, closing a stake of 151,706 shares — an estimated $1.06M sold.

Neuberger Berman Group first reported a position in MXCT in Q3 2021 and held it in 3 quarters. The position peaked at $1.81M in Q3 2021. 102 funds tracked by Wall St. Rank hold MXCT as of Q2 2022.

  • Neuberger Berman Group reported no remaining MaxCyte position as of Q2 2022 after selling out during the quarter.
  • Neuberger Berman Group sold 151,706 MaxCyte shares in Q2 2022, an estimated $1.06M.
  • Neuberger Berman Group first reported a position in MaxCyte in Q3 2021 and held it in 3 quarters.
  • Neuberger Berman Group's MaxCyte position peaked at $1.81M in Q3 2021.
  • 102 funds tracked by Wall St. Rank held MaxCyte as of Q2 2022.

Based on Neuberger Berman Group's 13F filing for Q2 2022, filed 15 Aug 2022.